The 3rd Helmholtz
*Nature-Medicine*
Diabetes Conference

September 19–21, 2015
Lenbach Palais, Munich, Germany

Topics

Insulin and Adipose Tissue Biology
Neurocircuits
Hypothalamus
Immunometabolism
Gut Hormones
Obesity and Body Weight Control
Liver and Metabolism
Islet Biology
Transcriptional Control
Metabolomics
Epigenetics

For detailed information please visit
www.nature.com/natureconferences/hmgu2015
Dear Friends and Colleagues,

We are excited to welcome you to our 3rd Helmholtz-Nature Medicine Diabetes Conference. On the heels of last year’s success, the Helmholtz Diabetes Center and Nature Medicine are continuing this recurring, high-impact meeting that brings together top leaders in the field of diabetes research.

Helmholtz Diabetes Center and Nature Medicine are co-organizing this meeting with the goal of facilitating a cure for all forms of diabetes. While the conference aims to cover all the major topic areas in the field, one hot topic for this year’s conference will be the role of the brain in metabolic control.

It is thanks to you that an incredible scientific program became possible, and we are especially grateful for generous support from the Helmholtz Zentrum München, Nature Medicine and sponsors from biotech and the pharmaceutical industry. We would like to specifically mention generous support by Sanofi and Novo Nordisk.

We are looking forward to getting yet one step closer to finding a cure for diabetes together with all of you!

Matthias, Stephan & Randy
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30–13:15</td>
<td>Registration</td>
</tr>
<tr>
<td>13:15–13:30</td>
<td>Welcome and Opening Remarks</td>
</tr>
<tr>
<td></td>
<td>Matthias Tschöp, Research Director, Helmholtz Diabetes Center, Helmholtz Zentrum München</td>
</tr>
<tr>
<td>13:30–15:00</td>
<td>Session 1: Insulin and Adipose Tissue Biology</td>
</tr>
<tr>
<td></td>
<td>Chairs: Matthias Blüher, Jens Brüning</td>
</tr>
<tr>
<td></td>
<td>MICHAEL CZECH, University of Massachusetts Adipocyte Lipogenesis in Control of Systemic Insulin Sensitivity</td>
</tr>
<tr>
<td></td>
<td>C. RONALD KAHN, Joslin Diabetes Center/ Harvard Medical School miRNAs in Adipose Tissue and Control of Systemic Metabolism</td>
</tr>
<tr>
<td></td>
<td>MATTHEW POY, Max Delbrueck Center for Molecular Medicine Neuronal Cadm1/SynCAM1 regulates energy and glucose homeostasis</td>
</tr>
<tr>
<td></td>
<td>CHRISTIAN WOLFRUM, Swiss Federal Institute of Technology (ETH) Zurich Regulation of White and Brown Adipose Tissue Homeostasis by Atypical Bile Acid Signaling</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>Coffee break</td>
</tr>
<tr>
<td>15:30–16:45</td>
<td>Session 2: Transcriptional Control</td>
</tr>
<tr>
<td></td>
<td>Chairs: Giles Yeo, Anette-Gabriele Ziegler</td>
</tr>
<tr>
<td></td>
<td>Special guest lecture: Helmholtz International Fellows Award</td>
</tr>
<tr>
<td></td>
<td>JOHN TODD, University of Cambridge From Genes to Therapeutic Strategies in Autoimmune Diabetes</td>
</tr>
<tr>
<td></td>
<td>KAREN RYAN, University of California at Davis Nuclear Receptor Signaling in the CNS Regulation of Stress and Metabolism</td>
</tr>
<tr>
<td>16:45–17:15</td>
<td>Coffee break</td>
</tr>
<tr>
<td>17:15–18:30</td>
<td>Session 3: Immunometabolism</td>
</tr>
<tr>
<td></td>
<td>Chairs: Carolin Daniel, Matthias von Herrath</td>
</tr>
<tr>
<td></td>
<td>YAZMÍN MACOTELA, University of Mexico Prolactin: A Guardian of Adipose Tissue Fitness and Metabolic Homeostasis</td>
</tr>
<tr>
<td></td>
<td>GREGORY STEINBERG, McMaster University Energy sensing and the regulation of metabolism</td>
</tr>
<tr>
<td></td>
<td>TAMAS HORVATH, Yale University AgRP neurons in control of peripheral immune cells</td>
</tr>
<tr>
<td></td>
<td>RANA GUPTA, University of Texas Southwestern Unlocking the Thermogenic Potential of Mature White Adipocytes in Obesity</td>
</tr>
<tr>
<td></td>
<td>PATRICK SEALE, University of Pennsylvania Molecular Regulation of Brown Fat Precursor Fate and Function</td>
</tr>
<tr>
<td></td>
<td>ZACH GERHART–HINES, University of Copenhagen Circadian Control of Brown Adipose Metabolism</td>
</tr>
<tr>
<td>19:00–22:30</td>
<td>Opening Reception at HEART restaurant &amp; bar*</td>
</tr>
</tbody>
</table>
08:30–09:00 Coffee break

09:00–10:30 Session 4: Gut Hormones
Chairs: Andrea Nawrocki, Susanna Hofmann

- DANIEL DRUCKER, University of Toronto
  Expanding the Spectrum of Actions for Enteroneuroendocrine Peptides

- RANDY SEELEY, University of Michigan
  Mechanisms of Bariatric Surgeries on Obesity and Diabetes

- ANA DOMINGOS, Gulbenkian Institute of Science
  NeuroImmunoMetabolism

- ANTONIO MOSCHETTA, University of Bari Italy
  The Metabolic Gut-Liver Axis: Focus on FXR-FGF19

10:30–11:15 Coffee break | Oktoberfest Trachten and Riflemen’s Parade viewing*

11:15–12:30 Session 5: Obesity and Body Weight Control
Chairs: Matthias Mann, Ruth Gimeno

- MICHAEL SCHWARTZ, University of Washington
  CNS Control of Glucose Homeostasis: Implications for Diabetes Pathogenesis and Treatment

- MICHAEL KRASHES, National Institutes of Health
  Motivational State Integration: Mimicking Physiological Hunger at the Neuron Level

- KEVIN WILLIAMS, University of Texas Southwestern
  Hypothalamic ER Stress in Obesity and Diabetes

- SERGE LUQUET, University Paris-Diderot
  Palatability Defines a Feeding Neurocircuitry Independent from AgRP Neurons

12:30–14:30 Buffet Lunch at restaurant

13:30–14:30 Scientific Round Table Session
(Fellows selected from abstracts paired with senior speakers & Chairs for project discussion)

14:30–16:15 Session 6: Hypothalamus
Chairs: Ingo Bechmann, Deniz Atasoy

- SABRINA DIANO, Yale University
  Ventromedial Hypothalamus Mitochondrial Dynamics Control Glucose Metabolism

- BRADFORD LOWELL, Beth Israel Deaconess Medical Center/Harvard Medical School
  Neural Circuitry Underlying MC4 Receptor Action

- ANDRÉ KLEINRIDDERS, German Institute for Human Nutrition
  Mitochondrial Function at the Crossroad of Central Insulin and Leptin Signaling

16:15–16:45 Coffee break

16:45–18:00 Session 7: Energy Metabolism
Chairs: Mathias Treier, Michael Mark

- ALEXANDER PFEIFER, University of Bonn
  Regulation of Brown Adipose Tissue by Auto-/Paracrine Factors - Pharmacological Implications

- DAVID OLSON, University of Michigan
  Functional Assessment of PVH Cell Types in Energy Balance

*street parade in front of the Lenbach Palais
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00–21:00</td>
<td>Speaker’s Dinner at HEART restaurant &amp; bar</td>
</tr>
<tr>
<td>19:00</td>
<td>Munich city tours*</td>
</tr>
<tr>
<td></td>
<td>*Optional event for conference attendees. Please ask for booking at the</td>
</tr>
<tr>
<td></td>
<td>registrations desk.</td>
</tr>
<tr>
<td>21:00</td>
<td>Special Performance by the The Sugar Daddies at Lenbach Palais* open for</td>
</tr>
<tr>
<td></td>
<td>everyone</td>
</tr>
<tr>
<td></td>
<td>*Please use the wristband in your congress bag or your badge for free</td>
</tr>
<tr>
<td></td>
<td>entrance.</td>
</tr>
</tbody>
</table>

We cordially invite you for next year’s conference

The 4th Helmholtz-Nature Medicine Diabetes Conference
September 17–19, 2016
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–08:30</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>08:30–10:00</td>
<td>Session 8: Liver and Metabolism</td>
<td>Chairs: Alessandro Pocai, Annette Schürmann</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DAVID MANGELSDORF, University of Texas Southwestern</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FGF21: Fasting to Feasting, Physiology to Pharmacology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MORRIS BIRNBAUM, Pfizer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Complex Regulation of Hepatic Metabolism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MARTIN MYERS, University of Michigan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Control of Gene Transcription and Physiology by Leptin</td>
</tr>
<tr>
<td>10:00–10:30</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>10:30–12:30</td>
<td>Session 9: Islet Biology</td>
<td>Chairs: Michael Roden, Jantje Gerdes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KLAUS KÄSTNER, University of Pennsylvania</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Regulation and Function of the Imprinted MEG3 Locus in Human Beta-Cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HEIKO LICKERT, Helmholtz Zentrum München</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Beta Cell Heterogeneity in the Islets of Langerhans</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LORI SUSSEL, Columbia University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Regulation of Pancreatic Islet Cell Fate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DAVID D’ALESSIO, Duke University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proglucagon Peptides in the Regulation of Insulin Secretion in Health and Diabetes</td>
</tr>
<tr>
<td>12:30–13:30</td>
<td>Buffet Lunch at restaurant</td>
<td></td>
</tr>
<tr>
<td>12:30–13:30</td>
<td>Scientific Exchange Table</td>
<td>Meet experts from MSD Sharp &amp; Dohme for informal scientific discussions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JEFFREY FRIEDMAN, The Rockefeller University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leptin and the Neural Circuit Controlling Food Intake and Metabolism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JOEL ELMQUIST, University of Texas Southwestern</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Using Mouse Genetics to Unravel the CNS Pathways Regulating Glucose Homeostasis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SCOTT STERNSON, Janelia Farms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neuronal Dynamics in the Melanocortin Circuit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LORI ZELTSER, Naomie Berrie Diabetes Center/ Columbia University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Developmental Influence on Circuits Regulating Body Weight</td>
</tr>
<tr>
<td>15:30–16:00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16:00–17:00</td>
<td>The Helmholtz Diabetes Lecture</td>
<td>BRUCE SPIEGELMAN, Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brown and Beige Fat: Basic Biology and a Novel Pathway of Thermogenesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Introduced by Stephan Herzig</td>
</tr>
<tr>
<td>17:00–17:10</td>
<td>Novo Nordisk - Helmholtz Young Investigator in Diabetes Award (HeIDi)</td>
<td>Introduction and Presentation of Award by Ulrich Stilz, Vice President Novo Nordisk</td>
</tr>
<tr>
<td>17:10–17:15</td>
<td>Nature Reviews Endocrinology Best Abstract Prize</td>
<td>Presentation by David Holmes</td>
</tr>
<tr>
<td>17:15–17:20</td>
<td>Closing Remarks by Randy Levinson, Senior Editor, Nature Medicine</td>
<td></td>
</tr>
</tbody>
</table>
Speakers

Plenary Speakers

Morris Birnbaum Pfizer, USA
Michael Czech University of Massachusetts, USA
David D’Alessio Duke University, USA
Sabrina Diano Yale University, USA
Daniel Drucker University of Toronto, CA
Joel Elmquist UT Southwestern, USA
Jeffrey Friedman The Rockefeller University, USA
Klaus Kästner University of Pennsylvania, USA
C. Ronald Kahn Joslin Diabetes Center/Harvard Medical School, USA
Heiko Lickert Helmholtz Zentrum München, DE
Bradford Lowell Beth Israel Deaconess Medical Center/Harvard Medical School, USA
David Mangelsdorf University of Texas Southwestern, USA
Ruslan Medzhitov Yale University, USA
Martin Myers University of Michigan, USA
Alexander Pfeifer University of Bonn, DE
Michael Schwartz University of Washington, USA
Randy Seeley University of Michigan, USA
Scott Sternson Janelia Farms, USA
Lori Sussel Columbia University, USA
John Todd University of Cambridge, UK
Lori Zeltser Naomie Berrie Diabetes Center/Columbia University, USA

Helmholtz Diabetes Lecture

Bruce Spiegelman Harvard Medical School, USA

Award Nominees / Short Talks

Melina Claussnitzer Harvard Medical School/MIT, USA
Ana Domingos Gulbenkian Institute of Science, PT
Zach Gerhart-Hines University of Copenhagen, DK
Rana Gupta University of Texas Southwestern, USA
André Kleinridders German Institute for Human Nutrition, DE
Michael Krashes National Institutes of Health, USA
Serge Luquet University Paris-Diderot, FR
Yazmín Macotela University of Mexico, MX
Antonio Moschetta University of Texas Southwestern, USA/IT
Ruben Nogueiras Pozo University of Santiago de Compostela, ES
David Olson University of Michigan, USA
Diego Perez-Tilve University of Cincinnati, USA
Matthew Rodeheffer Yale University, USA
Karen Ryan University of California at Davis, USA
Patrick Seale University of Pennsylvania, USA
Gregory Steinberg McMaster University, USA
Joshua Thaler University of Washington, USA
Kevin Williams University of Texas Southwestern, USA
Christian Wolfrum Swiss Federal Institute of Technology (ETH) Zurich, CH
Novo Nordisk - HeiDi-Award Committee

Magdalena Götz
Susanna Hofmann
Tamas Horvath
Heiko Lickert
Matthias Mann
Michael Roden
Anette Schürmann
Mathias Treier
Anette-Gabriele Ziegler

Conference Organizers

Matthias Tschöp
Helmholtz Zentrum München, Germany

Stephan Herzig
Helmholtz Zentrum München, Germany

Randy Levinson
Nature Medicine, USA

Conference Office

event lab. GmbH
Dufourstr. 15
04107 Leipzig, Germany

phone: +49 341 24 05 96 - 72
fax: +49 341 24 05 96 - 51
e-mail: diabetes2015@eventlab.org

The German Center for Diabetes Research (DZD)

The German Center for Diabetes Research (DZD) brings together experts in the field of diabetes research and combines basic research, translational research, epidemiology and clinical applications. The aim of the DZD is to develop novel strategies for successful, personalized detection, prevention and treatment of diabetes and its complications via an innovative, integrative research approach. Members of the network are Helmholtz Zentrum München – German Research Center for Environmental Health, the German Diabetes Center in Düsseldorf, the German Institute of Human Nutrition in Potsdam-Rehbrücke, the Paul Langerhans Institute Dresden of the Helmholtz Zentrum München at the University Medical Center Carl Gustav Carus Dresden and the Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Zentrum München at the Eberhard-Karls-University of Tübingen together with associated partners at the Universities in Heidelberg, Cologne, Leipzig, Lübeck and Munich. In 2015 the members of the Competence Network Diabetes mellitus were integrated as additional project partners.

For more information: [www.dzd-ev.de](http://www.dzd-ev.de)
SANOFI

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.

For more information: www.en.sanofi.com

AstraZeneca

About AstraZeneca in Diabetes

AstraZeneca is pushing the boundaries of science to create life-changing medicines that aim to reduce the global burden and complications of diabetes. Driven to redefine outcomes for diabetes patients, our current portfolio consists of the three newest classes of non-insulin, anti-diabetic treatments that support individualised treatment approaches: SGLT-2 inhibitors, GLP-1 receptor agonists and DPP-4 inhibitors. Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research programme. This commitment is advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination treatment approaches resulting in more patients achieving treatment success earlier in their disease progression. Our ambition is to reduce the long-term impact of diabetes. As a core strategic area for the company, we are focusing our research and development efforts in diverse populations and patients with significant co-morbidities, such as cardiovascular disease, heart failure, obesity, non-alcoholic steatohepatitis (NASH), and chronic kidney disease.

For more information: www.astrazeneca.com

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative „Making more Health“ and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

For more information: www.boehringer-ingelheim.com

NOVO NORDISK

Novo Nordisk is a global healthcare company. We combine world-class scientific, pharmaceutical, and clinical expertise with the highest ethical standards to continue to improve the quality of life of our patients. As the global leader in diabetes care, millions of patients worldwide rely on us to deliver cutting-edge treatments for their chronic disease every day. Additionally, we continue to invest in developing innovative treatments for obesity, haemophilia and growth disorders. Our success is built on more than 90 years of innovation and commitment to patients.

Headquartered in Denmark, Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries.

For more information: www.novonordisk.com
TSE Systems

TSE Systems has over 125 years of experience with high-quality laboratory supplies. Today, we are the leading developer and manufacturer of integrated metabolic and behavioral phenotyping equipment. Our particular focus is on automated, future proof, modular research platforms with the highest data reproducibility and standardization.

The latest developments in our PhenoMaster System include new hard-and software features including integrated scoring of operant behavior and an easy, economical upgrade path to continuous indirect high-speed calorimetry. Together with the newest guidelines in animal welfare we also established a clear evolutionary pathway to our PhenoWorld system for every PhenoMaster owner. Moreover, the embedding of continuous, economical, physiological monitoring (BP, Temp, HR, Activity, ECG, EMG) via Stellar Telemetry allows truly comprehensive integrated physiological, metabolic and behavioral long-term studies in group-housed animals with optimal animal welfare monitoring.

For more information: www.tse-systems.com

MSD

Today’s MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Connect with us on Twitter, Facebook and YouTube.

For more information: www.msd.de  www.univadis.de

Janssen Research & Development

At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients’ suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:

- cardiovascular and metabolism,
- immunology,
- infectious diseases and vaccines,
- neuroscience, and
- oncology

We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships. We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.

For more information: www.janssenrnd.com
Guidelines of the Code of Conduct

According to the guidelines of the FSA Code of Conduct or other codes, we disclose the financial support of:

- AstraZeneca € 10.000,-
- Boehringer Ingelheim Pharma GmbH & Co. KG € 10.000,-
- Janssen Research & Development, LLC € 6.000,-
- MSD Sharp & Dohme GmbH € 12.500,-
- Novo Nordisk A/S € 13.333,-
- Sanofi-Aventis Deutschland GmbH

DSI

Data Sciences International (DSI) is a pioneering biomedical research company focused on preclinical systems physiology and pharmacology. The recognized global leader in physiologic monitoring, DSI offers telemetry, instrumentation, software and services that facilitate accelerated, well-informed drug therapy and development decisions. DSI serves many industries including: pharmaceuticals, academia, contract research organizations, biological and chemical defense, the medical device, government, and biotechnology companies. DSI offer solutions that are tailored specifically to meet the unique research needs of its customers.

The HD-XG glucose telemetry implant offers preclinical diabetes and metabolic disease researchers a novel solution to obtain continuous, real-time blood glucose measurements in laboratory animals. Researchers can now collect data while reducing animal stress and measurement variability commonly associated with glucose test strip measurements. Adoption of the HD-XG in preclinical research studies will ultimately lead to the development of better drugs, better devices, and better therapies for humans.

For more information: www.glucosetelemetry.com

Bionorica SE

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals, markets products with proven efficacy, safety and quality in 50 countries worldwide today, with its headquarter in Neumarkt (Upper Palatinate), Germany.

The product range focuses mainly on diseases of the respiratory tract, the urinary tract, gynecological disorders and on medications for the treatment of pain.

Today, in terms of their pharmaceutical efficacy, safety and quality, modern, researched phytomedicines have to follow allopathic principles and have to find their place in evidence-based medicine. Fulfilling these requirements, plant-based medicines, backed by research, can be the preferred alternative to chemically and synthetically produced medicines. Bionorica’s products are prescribed and recommended by physicians and are sold exclusively in pharmacies. In terms of research and development of plant-based medicines, Bionorica sets the standard worldwide.

For more information: www.bionorica.de

Lonza

Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. Lonza is the trusted QC testing solution provider for the pharmaceutical and medical device industries. Lonza transforms its practical knowledge and technical expertise to deliver a portfolio of endotoxin, mycoplasma and microbial detection products, as well as paperless QC microbiology, software and services that support the critical needs of regulated manufacturing environments.

For more information: www.lonza.com
General Information

Conference Venue

Lenbach Palais
Ottostraße 6
80333 Munich, Germany

The event venue, Lenbach Palais is located in an historical 19th century palais. It is one of the few buildings in central Munich that was not destroyed in the war and its original architecture, including elegant marble floors and stucco ceilings, is still intact.

Password WiFi

Conference Room:  Name: tagung
Restaurant:  Name: restaurant
Password: tagung  Password: restaurant

Mediacheck

Please hand in your presentation, latest in the last break before your talk, directly to the technician in the Gobelin-Hall (conference hall) and check for complete and fluent presentation on the computer system provided. If you prefer using your own computer or other systems as windows, please make sure to bring your own adapter.

Parking

Some parking spaces are available directly in front of the conference venue. Please be aware that 2 hours are the maximum time for parking in these designated areas. Other basement car-parks are available in the near surroundings.

The Sugar Daddies live in concert

Lenbach Palais at 9 pm
Ottostraße 6, 80333 Munich
Please use the wristband in your congress bag or your badge for free entrance.

Getting to the Conference Venue

The Lenbach Palais is located in the center of the city and easily reached by public transportation:

U-Bahn U4 and U5, stop: Karlsplatz/Stachus (2-5 min from venue)
S-Bahn all lines, stop: Karlsplatz/Stachus (2-5 min from venue)
Tram No. 19, stop: Lenbachplatz (2-3 min from venue)
Tram No. 27, stop: Lenbachplatz (2-3 min from venue)